Both Novo Nord's Dual GIP/GLP-1 and Wegovy are new medications intended for treating diabetes and encouraging slimming. However, they work through slightly different pathways. Semaglutide is a GLP-1 receptor site stimulator, while Retatrutide acts as a dual GIP and GLP-1 agonist , possibly offering a more significant impact on combined blood sugar